Female Infertility Diagnosis and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
Female Infertility Diagnosis and Treatment Trends and Forecast
The future of the global female infertility diagnosis and treatment market looks promising with opportunities in the hospitals & clinic, homecare, and pathology & diagnostic centers markets. The global female infertility diagnosis and treatment market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 7.7% from 2024 to 2030. The major drivers for this market are growing prevalence of genetic disorders, such as Down syndrome, ONTD, and other disorders, increasing awareness towards avialable treatment, and technological advancement of assisted reproductive technology.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Female Infertility Diagnosis and Treatment by Segment
The study includes a forecast for the global female infertility diagnosis and treatment by treatment, diagnosis, end use, and region.
Female Infertility Diagnosis and Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:
- Drugs
- Surgery
- Intrauterine Insemination
- Assisted Reproductive Technology
Female Infertility Diagnosis and Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:
- Ovulation Testing
- Hysterosalpingography
- Hysteroscopy
- Imaging Testing
- Ovarian Reserve Testing
- Hormonal Level Testing
- Genetic Testing
- Others
Female Infertility Diagnosis and Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Hospitals and Clinics
- Homecare
- Pathology and Diagnostic Centers
- Others
Female Infertility Diagnosis and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Female Infertility Diagnosis and Treatment Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies female infertility diagnosis and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the female infertility diagnosis and treatment companies profiled in this report include-
- Bayer Ag
- Church & Dwight
- Genea
- Pfizer
- Vitrolife Sweden Ab
- Esco Group
- Fairhaven Health
- Ferring B.V.
Female Infertility Diagnosis and Treatment Market Insights
Lucintel forecasts that assisted reproductive technology is expected to witness highest growth over the forecast period due to on-going technological advancements, which includes in vitro fertilization (IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET for treating infertility in women.
Within this market, hospitals and clinics will remain the largest segment due to presence of large customer base and growing adoption of new technologically advanced practices by doctors.
Asia Pacific is expected to witness highest growth over the forecast period due to prevalence of infertility-related issues and increasing expenditure on healthcare in the region.
Features of the Global Female Infertility Diagnosis and Treatment Market
Market Size Estimates: Female infertility diagnosis and treatment market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Female infertility diagnosis and treatment market size by treatment, diagnosis, end use, and region in terms of value ($B).
Regional Analysis: Female infertility diagnosis and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different treatments, diagnosis, end uses, and regions for the female infertility diagnosis and treatment market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the female infertility diagnosis and treatment market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q.1 What is the female infertility diagnosis and treatment market size?
Answer: The global female infertility diagnosis and treatment market is expected to reach an estimated $2.0 billion by 2030.
Q.2 What is the growth forecast for female infertility diagnosis and treatment market?
Answer: The global female infertility diagnosis and treatment market is expected to grow with a CAGR of 7.7% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the female infertility diagnosis and treatment market?
Answer: The major drivers for this market are growing prevalence of genetic disorders, such as Down syndrome, ONTD, and other disorders, increasing awareness towards avialable treatment, and technological advancement of assisted reproductive technology.
Q4. What are the major segments for female infertility diagnosis and treatment market?
Answer: The future of the female infertility diagnosis and treatment market looks promising with opportunities in the hospitals & clinic, homecare, and pathology & diagnostic centers markets.
Q5. Who are the key female infertility diagnosis and treatment market companies?
Answer: Some of the key female infertility diagnosis and treatment companies are as follows:
- Bayer AG
- Church & Dwight
- Genea
- Pfizer
- Vitrolife Sweden AB
- Esco Group
- Fairhaven Health
- Ferring B.V.
Q6. Which female infertility diagnosis and treatment market segment will be the largest in future?
Answer: Lucintel forecasts that assisted reproductive technology is expected to witness highest growth over the forecast period due to on-going technological advancements, which includes in vitro fertilization (IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET for treating infertility in women.
Q7. In female infertility diagnosis and treatment market, which region is expected to be the largest in next 5 years?
Answer: Asia Pacific is expected to witness highest growth over the forecast period due to prevalence of infertility-related issues and increasing expenditure on healthcare in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the female infertility diagnosis and treatment market by treatment (drugs, surgery, intrauterine insemination, and assisted reproductive technology), diagnosis (ovulation testing, hysterosalpingography, hysteroscopy, imaging testing, ovarian reserve testing, hormonal level testing, genetic testing, and others), end use (hospitals & clinics, homecare, pathology & diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Please note: It will take 2-3 business days to deliver the report upon receipt the order.